1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Teyi Pharmaceutical Group Co., Ltd. Class A

Teyi Pharmaceutical Group Co., Ltd. Class A

SSZSE:002728
8.99
CNY
-0.05
(-0.55%)
0.11EPS
85.28P/E
4.70BMarket Cap
Oct 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.16
1.03
1.33
1.66
1.75
2.26
2.33
1.62
1.89
2.03
2.32
1.34
1.81
1.63
Basic EPS, GAAP
0.27
0.24
0.21
0.24
0.27
0.4
0.43
0.11
0.32
0.41
0.55
0.04
0.16
0.11
Free Cash Flow per Basic Share
0.1
0.09
-0.08
-0.18
0.16
0.09
0.23
0.2
0.37
0.64
0.24
-0.27
0.32
- -
Dividend per Share
0.05
0.05
0.04
0.08
0.08
0.3
0.38
0.42
0.34
0.34
0.32
0.36
0.05
0.15
Book Value per Share
1.19
1.88
2.05
2.26
2.66
2.82
2.93
2.71
2.9
3.12
3.94
3.45
3.55
3.47
Tangible Book Value per Share
1.13
1.83
0.35
0.57
0.98
0.99
1.01
0.87
1.26
1.55
2.58
2.13
2.25
2.17
Basic Weighted Avg Shares
295
334
388
395
393
391
396
390
401
438
460
512
510
503
Sales/Revenue/Turnover
343
345
517
656
687
885
921
633
758
887
1,067
688
925
822
Operating Margin (%)
26.39
23.81
17.79
18.02
19.59
24.11
25.78
17.42
24.15
24.7
29.12
4.64
8.86
7.29
Depreciation Expense
7
10
15
32
36
42
46
51
51
53
60
64
70
- -
Net Income, GAAP
81
80
81
95
106
156
172
44
127
178
253
20
82
54
Effective Tax Rate (%)
13.81
13.79
14.85
10.08
11.09
12.2
12.78
17.76
13.72
9.23
13.59
7.06
0.75
7.53
Profit Margin (%)
23.5
23.26
15.7
14.45
15.48
17.58
18.64
6.93
16.74
20.1
23.72
2.98
8.83
6.57
Working Capital
240
611
45
-45
359
290
162
51
216
20
639
355
403
373
LT Debt
- -
- -
178
178
424
394
304
272
285
- -
- -
- -
- -
- -
Total Equity
350
736
804
887
1,043
1,111
1,153
1,080
1,262
1,403
2,011
1,765
1,821
1,780
Return on Invested Capital (%)
25.56
14.39
8.18
7.31
6.88
8.72
8.47
2.25
5.97
8.49
10.99
0.97
3.67
2.59
Return on Capital (%)
25.35
13.72
8.87
8.98
8.15
10.58
10.52
3.71
7.53
9.81
11.71
1.11
3.93
2.7
Return on Common Equity (%)
25.35
14.77
10.53
11.21
11.02
14.44
15.17
3.92
10.84
13.37
14.83
1.09
4.55
3.02

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
264
289
424
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
513
513
513
Market Capitalization
5,569
5,657
4,697

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
858
892
1,006
Cash, Cash Equivalents & STI
336
365
556
Accounts Receivable, Net
74
53
55
Inventories
238
257
270
Total Current Liabilities
454
444
633
Payables & Accruals
- -
- -
- -
ST Debt
264
289
424
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.41%
12.45%
3.2%
Free Cash Flow
-30.02%
-65.15%
-220.89%
Net Income, GAAP
49%
95.75%
298.5%
Sales/Revenue/Turnover
8.93%
11.2%
34.42%
Total Cash Common Dividend
31.42%
-14.39%
-86.33%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
165
149
142
232
688
2025
295
196
- -
233
925
2026
210
183
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
-0.01
0.01
0.03
0.04
2025
0.06
0.01
- -
0.03
0.16
2026
0.05
0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.35
0.01
-0.01
0.36
2025
- -
- -
- -
-0.01
0.05
2026
- -
0.16
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Rong Huang Xu
Full Time Employees
1,621
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 9, 11, Changxing Road Taishan GD China 529200
IPO Date
Jul 31, 2014
Website
tczy.com.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Teyi Pharmaceutical Group Co., Ltd. (002728.SZ) is a China-based pharmaceutical company engaged in the research, development, production and sales of traditional Chinese patent medicines, chemical pharmaceutical preparations and chemical raw materials. The company, founded in 2002 and headquartered in Taishan City, Guangdong Province, offers a broad portfolio of products including cough and phlegm relievers such as cough suppressant tablets, Zhi Ke Bao tablets, Fei Li Cough Mixture and pediatric cough and wheezing tablets; kidney tonics including Yixin Shu tablets; anti-infection drugs; cardiovascular and cerebrovascular medicines; digestive system treatments like aluminum magnesium carbonate chewable tablets, Fengliao gastrointestinal health tablets and omeprazole enteric capsules; as well as dermatology products such as skin disease blood poison pills, hypoglycemic relief pills, single active parasitic granules, ginkgo biloba dispersible tablets and gingko biloba dispersible tablets; its chemical raw materials encompass aluminum carbonate, phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth series, citric acid series and zinc sulfate. Subsidiaries operate across Guangdong, Hainan, Anhui and other regions in China, serving medical and health sectors with a focus on respiratory, gastrointestinal, nephrology, endocrinology, rheumatology, tuberculosis and other therapeutic areas. In recent developments, the company reports robust financial growth with first-half 2025 revenue surging 56.5% year-over-year to RMB 491 million and net profit attributable to shareholders rising over 1,300% to RMB 38 million, driven by effective marketing reforms and restorative sales of cough remedies; it completed a share repurchase program acquiring 2.68% of its shares by May 2025 at a cost of RMB 101 million, while first-quarter 2025 revenue jumped 79% to RMB 295 million with net profit up 245%.